Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386532005> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4386532005 abstract "Abstract Background : The efficacy of enfortumab-vedotin as a third-line therapy for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune-checkpoint inhibitors was demonstrated in an enfortumab-vedotin -301 trial. Our study presents the analysis of enfortumab-vedotin treatment at our institution. Methods: We retrospectively analyzed patients with metastatic urothelial carcinoma who were treated with enfortumab-vedotin between January 2021 and April 2023. enfortumab-vedotin was administered at a dose of 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-body CT scans were performed every two–three months to assess the treatment response. Patient characteristics, treatment histories, response rates, progression-free survival, and adverse events were evaluated. Response rates were determined using RECIST version 1.1, and adverse events were recorded based on CTCAE version 4.03. Results: Among the 20 patients, 70% were male and 60% had bladder tumors. Most patients had lung (55%) or lymph node (50%) metastases. The median follow-up was 7.8 months, with 25% of the patients succumbing to the disease. The overall response rate was 45%. The median progression-free survival was 6.5 months. Severe adverse events occurred in 30% of patients. Conclusions: In this real-world study, enfortumab-vedotin demonstrated promising efficacy and manageable safety profiles in Japanese patients with metastatic urothelial carcinoma. The overall response rate and disease control rate were consistent with those of previous clinical trials, although a longer follow-up period was required. Our findings support enfortumab-vedotin use as a treatment option for patients with metastatic urothelial carcinoma who exhibit disease progression after platinum-based chemotherapy and immune-checkpoint inhibitors therapy." @default.
- W4386532005 created "2023-09-09" @default.
- W4386532005 creator A5001435424 @default.
- W4386532005 creator A5004714456 @default.
- W4386532005 creator A5024615970 @default.
- W4386532005 creator A5034304216 @default.
- W4386532005 creator A5034882456 @default.
- W4386532005 creator A5037056798 @default.
- W4386532005 creator A5037676296 @default.
- W4386532005 creator A5041089024 @default.
- W4386532005 creator A5049352867 @default.
- W4386532005 creator A5069649310 @default.
- W4386532005 creator A5069890206 @default.
- W4386532005 date "2023-09-09" @default.
- W4386532005 modified "2023-10-16" @default.
- W4386532005 title "Enfortumab-Vedotin for Metastatic Urothelial Carcinoma Refractory to Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: A Single Institution Experience" @default.
- W4386532005 cites W2559804019 @default.
- W4386532005 cites W2943108118 @default.
- W4386532005 cites W2964014383 @default.
- W4386532005 cites W2966500633 @default.
- W4386532005 cites W3005336040 @default.
- W4386532005 cites W3087464965 @default.
- W4386532005 cites W3127912627 @default.
- W4386532005 cites W3128646645 @default.
- W4386532005 cites W3157692800 @default.
- W4386532005 cites W4200121162 @default.
- W4386532005 cites W4293276514 @default.
- W4386532005 cites W4316143899 @default.
- W4386532005 doi "https://doi.org/10.21203/rs.3.rs-3277521/v1" @default.
- W4386532005 hasPublicationYear "2023" @default.
- W4386532005 type Work @default.
- W4386532005 citedByCount "0" @default.
- W4386532005 crossrefType "posted-content" @default.
- W4386532005 hasAuthorship W4386532005A5001435424 @default.
- W4386532005 hasAuthorship W4386532005A5004714456 @default.
- W4386532005 hasAuthorship W4386532005A5024615970 @default.
- W4386532005 hasAuthorship W4386532005A5034304216 @default.
- W4386532005 hasAuthorship W4386532005A5034882456 @default.
- W4386532005 hasAuthorship W4386532005A5037056798 @default.
- W4386532005 hasAuthorship W4386532005A5037676296 @default.
- W4386532005 hasAuthorship W4386532005A5041089024 @default.
- W4386532005 hasAuthorship W4386532005A5049352867 @default.
- W4386532005 hasAuthorship W4386532005A5069649310 @default.
- W4386532005 hasAuthorship W4386532005A5069890206 @default.
- W4386532005 hasBestOaLocation W43865320051 @default.
- W4386532005 hasConcept C121332964 @default.
- W4386532005 hasConcept C121608353 @default.
- W4386532005 hasConcept C126322002 @default.
- W4386532005 hasConcept C142424586 @default.
- W4386532005 hasConcept C143998085 @default.
- W4386532005 hasConcept C197934379 @default.
- W4386532005 hasConcept C2776694085 @default.
- W4386532005 hasConcept C2778822529 @default.
- W4386532005 hasConcept C2779984678 @default.
- W4386532005 hasConcept C2780352672 @default.
- W4386532005 hasConcept C2911057145 @default.
- W4386532005 hasConcept C3019882237 @default.
- W4386532005 hasConcept C71924100 @default.
- W4386532005 hasConcept C87355193 @default.
- W4386532005 hasConceptScore W4386532005C121332964 @default.
- W4386532005 hasConceptScore W4386532005C121608353 @default.
- W4386532005 hasConceptScore W4386532005C126322002 @default.
- W4386532005 hasConceptScore W4386532005C142424586 @default.
- W4386532005 hasConceptScore W4386532005C143998085 @default.
- W4386532005 hasConceptScore W4386532005C197934379 @default.
- W4386532005 hasConceptScore W4386532005C2776694085 @default.
- W4386532005 hasConceptScore W4386532005C2778822529 @default.
- W4386532005 hasConceptScore W4386532005C2779984678 @default.
- W4386532005 hasConceptScore W4386532005C2780352672 @default.
- W4386532005 hasConceptScore W4386532005C2911057145 @default.
- W4386532005 hasConceptScore W4386532005C3019882237 @default.
- W4386532005 hasConceptScore W4386532005C71924100 @default.
- W4386532005 hasConceptScore W4386532005C87355193 @default.
- W4386532005 hasLocation W43865320051 @default.
- W4386532005 hasOpenAccess W4386532005 @default.
- W4386532005 hasPrimaryLocation W43865320051 @default.
- W4386532005 hasRelatedWork W2289712604 @default.
- W4386532005 hasRelatedWork W2351476339 @default.
- W4386532005 hasRelatedWork W2367973749 @default.
- W4386532005 hasRelatedWork W2569260518 @default.
- W4386532005 hasRelatedWork W2605347262 @default.
- W4386532005 hasRelatedWork W2755349712 @default.
- W4386532005 hasRelatedWork W3031735911 @default.
- W4386532005 hasRelatedWork W3135121572 @default.
- W4386532005 hasRelatedWork W3200773128 @default.
- W4386532005 hasRelatedWork W4295429000 @default.
- W4386532005 isParatext "false" @default.
- W4386532005 isRetracted "false" @default.
- W4386532005 workType "article" @default.